The FDA’s Own Scientists Said No to All Seven. Its Advisory Committee Said Yes to Six.

Last reviewed: September 2, 2026

The vote nobody reported right

Is BPC-157 banned? No. It is not banned, it is not approved, and nothing about its legal status changed on July 23–24, 2026. What did happen is more interesting than either “banned” or “approved”. and almost nobody is reporting it accurately.

The FDA’s own review teams recommended that all seven peptides. both forms of each. NOT be added to the 503A Bulks List. Every one. BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, semax.

The advisory committee then voted to add six of the seven anyway.

An FDA advisory committee overruled the FDA’s own scientists on six of seven substances. That’s the story. Everyone else ran either a ban headline or a win headline. Nobody ran the actual event.

These are recommendations, not law. The FDA has not made a final ruling. Nothing about what is legal today has changed.

The petitioners walked away. FDA reviewed all seven anyway.

There’s a second fact the coverage missed. FDA’s own presentation slides state it plainly: “The nomination was withdrawn, and FDA is evaluating these substances at its discretion.”

The petitioners who asked for these substances to be added to the 503A Bulks List withdrew their nominations. FDA reviewed all seven anyway, on its own initiative, after the requesters walked away.

This reframes the meeting. This wasn’t industry pressing a case and winning. The people who wanted these substances listed gave up. and FDA’s own scientists then said no. and the advisory committee voted yes to six of them regardless.

What is the 503A Bulks List?

An FDA-maintained list of bulk drug substances that compounding pharmacies may use under Section 503A of the Federal Food, Drug, and Cosmetic Act. Codified at 21 C.F.R. § 216.23.

If a substance is on the list, a compounding pharmacy may compound it with a prescription for an individual patient. If it is not on the list, they cannot.

Being on the list is not FDA approval. It is not a finding of safety or efficacy. It is not an approved drug. It does not establish an approved indication. It means the substance is permitted for compounding use. nothing more.

This vote was about 503A compounding only. It says nothing about 503B outsourcing facilities, research-use-only vendors selling direct to consumers, or veterinary use. For background on what the compounding review process means, see our August 17 analysis.

What was actually voted on: 14 votes, not 7

Each substance was voted on in two forms. free base and acetate. voted separately. That’s 14 votes, not 7. The committee met July 23–24, 2026 at the FDA White Oak campus. Public docket: FDA-2025-N-6895.

July 23: BPC-157, KPV, TB-500, MOTS-c (free base and acetate of each).

July 24: Emideltide (DSIP), Epitalon, Semax (free base and acetate of each).

The seven peptides, compound by compound

A note on the numbers: FDA has not published official meeting minutes or a transcript. The tallies below are reported figures from regulatory and trade press coverage. not from FDA’s own records. We’re showing you the numbers because they’re useful, and we’re telling you their source because that’s the difference between a source you can check and one you can’t. Full details in “What we could not verify” below.

BPC-157

Use FDA evaluated: Ulcerative colitis.

Committee recommendation: Recommended for inclusion. Reported tally: 8–6–1.

FDA staff recommendation: Do not include. FDA concluded BPC-157 is “not well-characterized.” BPC-157 “is a common name and not a USAN, INN, or IUPAC name.” FDA “has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name.”

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List. On the World Anti-Doping Agency prohibited list under the non-approved substances section (S0). prohibited precisely because no regulatory authority has approved it for human use. Not a component of an approved product in any country. Not found in the European, Japanese, or International Pharmacopeias.

KPV

Use FDA evaluated: Wound healing and inflammatory conditions.

Committee recommendation: Recommended for inclusion. Reported tally: 8–6–1.

FDA staff recommendation: Do not include. “Not well-characterized.” No USP monograph. Absent immunogenicity and aggregation data. Notably, FAERS retrieved zero adverse event reports for KPV. FDA still concluded not well-characterized. No reports is not the same as shown safe.

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List. Also appears in the Peptexa pets guide under veterinary status, which is a separate regulatory framework.

TB-500

Use FDA evaluated: Wound healing.

Committee recommendation: Recommended for inclusion. Reported tally: 8–6–1.

FDA staff recommendation: Do not include. “Not well-characterized.”

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List. On the World Anti-Doping Agency prohibited list under the Growth Factors and Growth Factor Modulators section (S2.3).

Both BPC-157 and TB-500 are commonly discussed together. see our Peptide Stacks hub for more on combination protocols.

MOTS-c

Use FDA evaluated: Obesity and osteoporosis.

Committee recommendation: Recommended for inclusion. Reported tally: 7–5–2.

FDA staff recommendation: Do not include. “Not well-characterized.”

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List. Also appears in the Peptexa pets guide under veterinary status, which is a separate regulatory framework.

Semax

Use FDA evaluated: Cerebral ischemia, migraine, trigeminal neuralgia.

Committee recommendation: Recommended for inclusion. Reported tally: 8–5–1.

FDA staff recommendation: Do not include. “Not well-characterized.” FDA noted approved drugs already exist for the evaluated indications.

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List.

Epitalon (also written Epithalon)

Use FDA evaluated: Insomnia.

Committee recommendation: Recommended for inclusion. Reported tally: 7–4–1.

FDA staff recommendation: Do not include. “Not well-characterized.”

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List. Also appears in the Peptexa pets guide under veterinary status, which is a separate regulatory framework.

Emideltide (DSIP)

Use FDA evaluated: Opioid withdrawal, chronic insomnia, narcolepsy.

Committee recommendation: Recommended AGAINST. Failed by a single vote.

FDA staff recommendation: Do not include. “Not well-characterized.”

Regulatory status today: Not FDA-approved. Not on the 503A Bulks List.

What FDA actually objected to

FDA’s review teams used the same core conclusion for all seven: “not well-characterized.” The specific grounds, from the FDA’s own presentation slides:

Naming. BPC-157 “is a common name and not a USAN, INN, or IUPAC name.” FDA “has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name.” Different products are sold under the name BPC-157, and they are not all the same thing.

Missing characterization data. Impurities, aggregates, microbial bioburden, and bacterial endotoxin testing were absent. No USP drug substance monograph exists. The Certificate of Analysis found in the public domain for BPC-157 free base lacked impurity limits and aggregation data.

Immunogenicity. BPC-157 “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities,” particularly via subcutaneous and nasal routes.

No human safety data via proposed routes. FDA “found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA.” The human studies FDA did identify used different routes entirely.

The nomination paperwork didn’t identify the substances correctly. This is the concrete evidence behind “not well-characterized,” and it’s in FDA’s own annotations. For TB-500, FDA records that the nomination’s CAS number “matches neither TB-500 free base nor TB-500 acetate,” the molecular formula “matches neither TB-500 free base nor TB-500 acetate,” the Certificate of Analysis molecular formula “is not legible,” and the CoA was for TB-500 acetate while the nominated substance was TB-500 free base. For epitalon, one of two nominations supplied no UNII code at all, and both attached a CoA for the acetate form. The paperwork asking FDA to permit these substances failed to say which molecule it was talking about.

The indications nobody noticed

The use FDA evaluated is often not what the compound is popularly sold for.

BPC-157 was evaluated for ulcerative colitis. not joint repair, not tendon healing, not post-surgical recovery. Epitalon was evaluated for insomnia. not longevity, not telomerase activation, not anti-aging. MOTS-c was evaluated for obesity and osteoporosis. not longevity, not metabolic optimization. even though longevity was in the original nomination. FDA chose not to evaluate it.

Any reading of this vote as “the FDA blessed BPC-157 for healing” or “epitalon for anti-aging” is wrong. The committee voted on specific evaluated indications. Not on how these compounds are marketed. Not on what people buy them for.

This is the single most useful correction in this post. The vote does not validate what people buy these compounds for.

The safety record FDA found

FDA identified five human studies for BPC-157. All small. All short. All exploratory. None used the routes people typically use today:

• Up to 2 mg/kg rectal enema daily for 8 days, 24 healthy subjects
• 80 mg rectal enema daily for 2 weeks, approximately 26 subjects with ulcerative colitis
• 2–4 mg intra-articular, 1–2 doses, 17 subjects with knee pain
• 10 mg intravesical, single procedure, 12 subjects with interstitial cystitis
• 10 mg then 20 mg IV, 2 healthy subjects

FDA noted these were short, small, exploratory, with unclear safety monitoring. The most frequent adverse events in the enema studies were headache and flatulence.

FDA’s FAERS search retrieved three reports for BPC-157:

1. A 55-year-old woman, compounded BPC-157 injection. 9 days of injection-site redness and swelling.
2. A 28-year-old man, BPC-157 acetate subcutaneous. shortness of breath, ER visit.
3. A 40-year-old woman, BPC-157 and TB-500 subcutaneous twice daily. diffuse hyperpigmentation and gingival darkening, reproducible on rechallenge.

FDA cautions that FAERS attribution is unclear and reporting is voluntary. The reproducible-on-rechallenge detail is the one worth noting.

For KPV: zero FAERS reports. FDA still concluded “not well-characterized.” No adverse event reports is not the same as shown safe.

What happens next

The recommendation is non-binding. FDA’s own language: advisory committees “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” In this case, FDA staff recommended the opposite of what the committee voted.

Adding a substance to the 503A Bulks List requires rulemaking: FDA internal review, notice of proposed rulemaking, a 60–90 day public comment period, a final rule, then an effective date. Reported estimates put internal review alone at roughly 3–12 months.

No timeline has been announced. The FDA is not required to follow the committee’s recommendation. Nothing on the 503A Bulks List has been added or removed yet.

When and if a final rule adds these substances, compounding pharmacies would be able to compound them under 503A with a prescription. Until then, the current legal status of each substance is unchanged.

We will update this post and each affected compound profile when the FDA acts.

FAQ

Sources

Every fact in this post is drawn from FDA’s own meeting materials. Vote tallies are reported figures from regulatory and trade press. see “What we could not verify” above.

• FDA meeting page
• FDA Briefing Document
• Final Agenda
• Final Meeting Roster
• Voting Questions
• July 23 FDA Presentations
• July 24 FDA Presentations
• Federal Register notice
• Public docket: FDA-2025-N-6895

Educational information only. Not medical or legal advice. Peptexa does not sell peptides. We publish verified information.

This post will be updated when the FDA issues a final ruling or when official meeting minutes are published.

We read the FDA documents, not the coverage.